AMENDMENTS TO THE CLAIMS

1. Canceled

2. (**Currently Amended**) An isolated tumor antigen peptide that is a partial peptide of a protein consisting of the amino acid sequence of SEQ ID NO: 2, wherein the peptide comprises the amino acid sequence of SEQ ID NO: 3 and binds to an HLA-A24 antigen and is recognized by cytotoxic T lymphocytes.

3-10. Canceled

- 11. (**Currently Amended**) A pharmaceutical composition for treating tumors, which comprises as an active ingredient at least one of substances selected from the tumor antigen peptides according to claim 2, 3 or 16, and a pharmaceutically acceptable carrier.
- 12. (Currently Amended) A recombinant polypeptide produced by expressing a recombinant DNA comprising at least one polynucleotide that encodes the tumor antigen peptide according to claim 2,3 or 16.
- 13. (**Previously Presented**) A pharmaceutical composition for treating a tumor, which comprises as an active ingredient the recombinant polypeptide of claim 12, in an amount effective for treating said tumor and a pharmaceutically acceptable carrier.
- 14. (**Previously Presented**) A diagnostic agent for tumors, which comprises the tumor antigen peptide according to claim $2\frac{3}{2}$ or 16.

Docket No.: 0020-5224P

- 15. (**Original**) A diagnostic agent for tumors, which comprises the recombinant polypeptide of claim 12.
- 16. (**Previously Presented**) The isolated tumor antigen peptide according to claim 2 consisting of the amino acid sequence of SEQ ID NO:3.

17-18. Canceled